BIOMARIN PHARM (NASDAQ:BMRN)
16.97
0.37 (2.13%)
| BIOMARIN PHARM (NASDAQ:BMRN) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $17.34 | 52 Week High | $21.23 | ||
| Open | $17.25 | 52 Week Low | $9.93 | ||
| Day High | $17.25 | P/E | 99.82 | ||
| Day Low | $16.92 | EPS | $0.17 | ||
| Volume | 721,377 | ||||
| More BMRN Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| WFMI | 6 | LJPC | 5 |
| HPQ | 5 | GENZ | 5 |
| PCLN | 4 | BIDU | 4 |
| CBS | 4 | NILE | 4 |
| CSGP | 3 | NILE | 3 |
| DBRN | 3 | AAP | 3 |
Entities who have mentioned BMRN
- Citi | View Related Stories »
- Robert W Baird | View Related Stories »
- Dividend | View Related Stories »
- Thomas Weisel Partners Group | View Related Stories »
- UBS | View Related Stories »
- Morgan Stanley | View Related Stories »
- Wachovia | View Related Stories »
- Banc of America | View Related Stories »
- Barclays | View Related Stories »
- Soleil Securities | View Related Stories »
- Credit Suisse | View Related Stories »
- Morgan Joseph | View Related Stories »
- Crude Oil | View Related Stories »
- Trading Radar | View Related Stories »
- Roth Capital | View Related Stories »
- Goldman Sachs | View Related Stories »
- Notable Analyst Rating Changes | View Related Stories »
- Collins Stewart | View Related Stories »
- After-Hours Movers | View Related Stories »
- Piper Jaffray | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- SAC Capital | View Related Stories »
- Steven A. Cohen | View Related Stories »
- Goldman Sachs Conviction Buy List | View Related Stories »
- David Moenning | View Related Stories »
View All Major News StreetInsider.com Major News for BMRN
- BioMarin Pharmaceutical (BMRN) Tops Q3 EPS by 12c; Guides
- BioMarin Pharmaceutical (BMRN) Tops Q2 EPS By 10c; Raises Low-End of FY Revenue Guidance
- BioMarin (BMRN) Reports Mixed Q4 Earnings; Guides FY09 Sales
View All ReportsStreetInsider.com Reports on BMRN
- BioMarin (BMRN) Responds to News of Contamination at Genzyme (GENZ) Plant; Says Aldurazyme, Naglazyme Won't Be Impacted
- Morgan Joseph Reiterates a 'Buy' on BioMarin Pharmaceutical (BMRN)
- Credit Suisse Upgrades BioMarin Pharmaceutical (BMRN) to Overweight
- BioMarin Pharmaceutical (BMRN) Tops Q3 EPS by 12c; Guides
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
View All Press ReleasesCompany Press Releases on BMRN
- Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme
- United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food
- BioMarin to Present at the Credit Suisse Healthcare Conference
- BioMarin Announces Third Quarter 2009 Financial Results
- BioMarin to Present at the Oppenheimer Healthcare Conference
StreetInsider Reports on BMRN by Category
View All BlogsBlogs on BMRN
- Thursday's Options Recap
- Wall Street Breakfast: Must-Know News
- FDA Calendar Updates: BioMarin, OSI, Roche, Abraxis, Johnson & Johnson
- Passport Capital Chooses Gold Over Education
- Spectrum Pharmaceuticals: Undervalued Growth Company with Strong Late-Stage Pipeline
View All FilingsSEC Filings on BMRN
- Form 10-Q BIOMARIN PHARMACEUTICAL For: Sep 30
- Form 8-K BIOMARIN PHARMACEUTICAL For: Oct 28
- Form 8-K BIOMARIN PHARMACEUTICAL For: Oct 20
Comments on recent BMRN articles
Comments on BMRN
No comments are currently available.
on Mar 20, 2009
at 03:23 PM Biomarin and Genzyme It makes a lot of sense for Genzyme to acquire Biomarin, but this has been obvious for a long time, and Genzyme has chosen not to bite. Also, Biomarin's management may not be interested in selling even at the thirty dollar level.
Article: Baird Said a Genzyme (GENZ) Takeover Of BioMarin (BMRN) Makes Sense To Them